Geron Corporation Revenue and Competitors

Claim your profile



Total Funding



Estimated Revenue & Valuation

  • Geron Corporation's estimated annual revenue is currently $403k per year.(i)
  • Geron Corporation's estimated revenue per employee is $1,465
  • Geron Corporation's total funding is $236.7M.
  • Geron Corporation's current valuation is $386.3M. (January 2022)

Employee Data

  • Geron Corporation has 275 Employees.(i)
  • Geron Corporation grew their employee count by 10% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
Add Company

Geron Corporation is a development stage biopharmaceutical company focused on developing and commercializing therapeutic and diagnostic products for applications in oncology and regenerative medicine, and research tools for drug discovery. The Company's product development programs are based upon three patented core technologies: telomerase, human embryonic stem cells and nuclear transfer. The Company is working to develop anti-cancer therapies based on telomerase inhibitors, oncolytic (cancer-killing) viruses and telomerase vaccines. The Company also intends to continue to develop and commercialize products using telomerase as a marker for cancer diagnosis, prognosis, patient monitoring and screening.



Total Funding


Number of Employees


Revenue (est)


Employee Growth %





Geron Corporation News

2022-03-22 - Geron Corporation Announces the Pricing of its Public ...

Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class...

2022-03-22 - Geron slumps on pricing $75M stock and warrants offering

Geron Corporation (NASDAQ:GERN) slumps 18% after hours after the firm has ... All of the securities in the offering are being sold by Geron.

2022-03-22 - Geron Corp. Shares Fall Premarket After Public Offering GERN

By Colin Kellaher. Shares of Geron Corp. slid nearly 20% in premarket trading Wednesday after the biopharmaceutical company said it was...

2021-01-26 - Arriello Announces Signing of First US Company to Use IntelliCASE for Clinical Pharmacovigilance Reporting

The app is completely intuitive and convenient to use, removing any practical or logistical barriers to Adverse Event reporting. DUBLIN (PRWEB) January 26, 2021 Arriello, a global expert in pharmacovigilance consulting and life science outsourcing services, has today announced that Geron Corpo ...

2010-10-12 - First patient receives embryonic stem cells in spinal injury trial

Physicians injected the first-ever patient with millions of stem cells derived from human embryos in a clinical trial aimed at proving the treatment is safe for people with spinal cord injuries. The trial, sponsored by Geron Corp. (NSDQ:GERN), calls for patients to receive the injection within ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding